Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Baxter International ( (BAX) ).
In August 2025 Baxter appointed Andrew Hider as president, CEO and director after a robust search overseen by independent directors, and in connection with his arrival the board separated the CEO and chair roles, naming former interim CEO Brent Shafer as non‑executive chair. The company has continued to refresh its board, adding three independent directors over the past three years, including former Biogen CFO Michael McDonnell in February 2026, while repositioning leadership with interim CFO Anita Zielinski following the March 2026 departure of former CFO Joel Grade.
Operationally, Baxter completed the strategic initiatives announced in January 2023, culminating in the January 2025 divestiture of its Vantive kidney care segment, and reported 3% operational sales growth, modest operating margin expansion, and a 20% increase in adjusted diluted EPS from continuing operations in 2025. Management outlined a disciplined capital allocation plan prioritizing debt reduction to reach roughly 3.0x net leverage by the end of 2026, maintaining its minimal dividend, funding R&D and growth‑oriented capex, and pursuing targeted M&A, while emphasizing extensive shareholder engagement and refreshed sustainability and corporate responsibility commitments following a 2025 double materiality assessment.
The most recent analyst rating on (BAX) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Baxter International stock, see the BAX Stock Forecast page.
Spark’s Take on BAX Stock
According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.
The score is held down primarily by weakening financial performance (unstable profitability and sharply deteriorated cash flow) and continued execution/margin risks highlighted in guidance (tariffs, Novum disruption, and back-half-weighted recovery). A short-term technical rebound and a moderate dividend provide partial support, but valuation remains difficult to underwrite with a negative P/E.
To see Spark’s full report on BAX stock, click here.
More about Baxter International
Baxter International is a leading global medical technology company focused on medically essential products and redefining healthcare delivery to advance its mission to “Save and Sustain Lives.” From its continuing operations, it generated $11.2 billion in 2025 revenue across medical products and therapies, healthcare systems and technologies, pharmaceuticals, and other offerings, with products sold in more than 100 countries and a workforce of about 37,500 employees.
Average Trading Volume: 9,631,795
Technical Sentiment Signal: Sell
Current Market Cap: $8.79B
See more data about BAX stock on TipRanks’ Stock Analysis page.